Key facts
- This page summarizes Jon Congleton's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Jun 2024, 17:44.
Jon Congleton - 17 Jun 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MLYS
- Reported as of
- 17 Jun 2024
- Net transaction value
- -$592,022
- SEC form
- 4
- Accepted by SEC
- 20 Jun 2024, 17:44:01 UTC
- Prior SEC filing
- 14 Jun 2024
- Next SEC filing
- 12 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam Levy, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jon Congleton filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 20 Jun 2024.
Change
- Previous filing in this sequence was filed on 14 Jun 2024.
- Current net transaction value: -$592,022.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MLYS
transaction
Common Stock
Sale
- Transaction value
- $217,712
- Shares
- -17,766
- Change %
- -1.8%
- Price
- $12.25
- Shares after
- 958,505
- Date
- 17 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
MLYS
transaction
Common Stock
Sale
- Transaction value
- $199,073
- Shares
- -16,607
- Change %
- -1.7%
- Price
- $11.99
- Shares after
- 941,898
- Date
- 18 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F3
MLYS
transaction
Common Stock
Sale
- Transaction value
- $175,237
- Shares
- -14,940
- Change %
- -1.6%
- Price
- $11.73
- Shares after
- 926,958
- Date
- 20 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.
Footnote F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.0982 to $12.4627. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
Footnote F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.76 to $12.12.
Footnote F4
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.525 to $12.05.